RIGL - Rigel Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.88
-0.09 (-2.27%)
As of 3:48PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.97
Open4.03
Bid3.89 x 5200
Ask3.90 x 5200
Day's Range3.86 - 4.03
52 Week Range1.94 - 4.33
Volume423,510
Avg. Volume1,508,653
Market Cap561.26M
Beta1.04
PE Ratio (TTM)-5.75
EPS (TTM)-0.68
Earnings DateOct 30, 2017 - Nov 3, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.33
Trade prices are not sourced from all markets
  • Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
    PR Newswire10 days ago

    Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif. , Oct. 10, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL) today announced the closing of its previously announced underwritten public offering of 20,815,000 ...

  • ACCESSWIRE10 days ago

    Rigel Pharmaceuticals, Fostamatinib Clinical Trials and Pipeline Review

    NEW YORK, NY / ACCESSWIRE / October 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 12.1% Higher
    Zacks15 days ago

    Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 12.1% Higher

    Rigel Pharmaceuticals (RIGL) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.

  • Rigel Announces Pricing Of Public Offering Of Common Stock
    PR Newswire16 days ago

    Rigel Announces Pricing Of Public Offering Of Common Stock

    SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL), today announced the pricing of its previously announced underwritten public offering of 18,100,000 ...

  • Rigel Announces Proposed Public Offering Of Common Stock
    PR Newswire17 days ago

    Rigel Announces Proposed Public Offering Of Common Stock

    SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that it intends to offer and sell up to $40,000,000 of shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to purchase up to an additional $6,000,000 of shares of common stock sold in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • ACCESSWIRE17 days ago

    Today's Research Reports on Stocks to Watch: Catabasis Pharmaceuticals and Rigel Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 3, 2017 / Shares of Catabasis surged on Monday after announcing this past Friday that it would be presenting data on its investigational oral small molecule Edasalonexent ...

  • MarketWatch17 days ago

    Rigel shares soar 14% on positive data in early study of treatment for rare form of anemia

    Rigel Pharmaceuticals Inc. said Tuesday a phase 2 study of a treatment for patients with warm antibody autoimmune hemolytic anemia, or AIHA, met its main goal in stage 1 of the trial, sending its stock ...

  • Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study
    PR Newswire17 days ago

    Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study

    SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that the company recently completed enrollment of Stage 1 of its Phase 2, open-label, multi-center, two-stage study of its investigational drug fostamatinib for the treatment of patients with warm antibody AIHA. On a top-line, preliminary basis, the Phase 2 study has achieved the pre-specified primary efficacy endpoint for Stage 1. This Phase 2 study, also known as the SOAR study, is evaluating the safety and efficacy of fostamatinib in patients with warm antibody AIHA who have previously received at least one treatment for this disease, but did not have a meaningful benefit and are still anemic.

  • Rigel Provides Update on FDA Review of Fostamatinib for ITP
    PR Newswire18 days ago

    Rigel Provides Update on FDA Review of Fostamatinib for ITP

    SOUTH SAN FRANCISCO, Calif., Oct. 2, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that during the company's mid-cycle meeting with the U.S. Food and Drug Administration (FDA) the FDA indicated that, at this point, it is not planning to hold an Oncology Drugs Advisory Committee (ODAC) meeting to discuss the New Drug Application (NDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP).  Additionally, the FDA indicated that it anticipates meeting the Prescription Drug User Fee Act (PDUFA) action date for the application review, which is April 17, 2018. In an earlier communication, the FDA had conditionally approved the proprietary name TavalisseTM.